iBio and AzarGen Biotechnologies enter second Statement of Work

Mar 26, 2020

iBio and AzarGen Biotechnologies announce they have entered into a second Statement of Work under their Master Joint Development Agreement. Under this agreement, iBio will assist AzarGen in the manufacture and characterisation of supplies to enable pre-clinical studies of a rituximab biosimilar.

Print Page Mail Article